‫يوم‬ 90 ‫في‬ ‫إيجابية‬ ‫(العدد=2)‬ 5% ‫ا‬ ً ‫يوم‬ 90 ‫ملدة‬ ‫الوفيات‬ ‫معدل‬ ‫كان‬ .)p=0.631( ‫الثانية‬ ‫الثانية‬ ‫املجموعة‬ ‫في‬ ‫(العدد=1)‬ 2.5% ‫مقابل‬ ‫األولى‬ ‫املجموعة‬ ‫في‬ ‫في‬ ‫مرضى‬ 3 ‫في‬ ‫اجلمجمة‬ ‫داخل‬ ‫نزيف‬ ‫أعراض‬ ‫وحظ‬ ٌ ‫ل‬ .)p=0.556( .)p=0.077( ‫األولى‬ ‫املجموعة‬ ‫في‬ ‫وصفر‬ ‫الثانية‬ ‫املجموعة‬ ‫ا‬ ً ‫عملي‬ ً ‫بديال‬ ‫تكون‬ ‫أن‬ ‫ميكن‬ ‫التيبالز‬ ‫من‬ ‫منخفضة‬ ‫جرعة‬ ‫اخلالصة:‬ ‫فترة‬ ‫في‬ ‫خاصة‬ ‫احلادة‬ ‫الدماغية‬ ‫بالسكتة‬ ‫املصابني‬ ‫املصريني‬ ‫للسكان‬ ‫ساعات.‬ 4.5 ‫إلى‬ 3 ‫من‬ ‫تتراوح‬ Objectives: To assess low dose altepase outcome and safety in comparison with a standard-dose regimen for acute ischemic stroke treatment in Egyptian patients. Materials: An observational prospective cohort nonrandomized single blinded study was carried out during the period from November 2017 to December 2018. Eighty Egyptian acute ischemic stroke patients, all eligible for intravenous alteplase, were subdivided into 2 groups )40 patients in each group(. Patients were thrombolysed at a dose of 0.6 mg/kg in the first group Original Article and 0.9 mg/kg in the second group. Both groups were compared in regard to safety and outcome. Safety was expressed by the rate of symptomatic intracranial hemorrhage )SICH( and 3 months mortality, while outcome was expressed by favorable outcomes at three months )modified Rankin Scale ]mRS[ of 0 to 2(. Results: In the first group, 69.2% )n=27( achieved favorable outcomes at 90 days compared with 64.1% )n=25( in the second group )p=0.631(. Ninety-day mortality was 5% )n=2( in the first group versus 2.5% )n=1( in the second group )p=0.556(. Symptomatic intracranial hemorrhage was noted in 3 patients in the second group and zero patients in the first group )p=0.077(. Conclusion:Low-dose alteplase could be a practical alternative for Egyptian populations with acute ischemic stroke especially in 3 to 4.5 hours window.